NEW YORK, Jan. 10, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against KLX, Inc. (“KLX” or the “Company”) (NASDAQ:KLXI), and certain of its officers. The class action, filed in United States District Court, Southern District of Florida, is on behalf of a class consisting of all persons or entities who purchased KLX securities between March 9, 2015 and November 11, 2015 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
If you are a shareholder who purchased KLX securities during the Class Period, you have until March 7, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
KLX is the world’s leading provider of aerospace fasteners, consumables, and logistics services globally as KLX Aerospace Solutions. It also provides oilfield services and associated rental equipment across North America as KLX’s Energy Services Group (“ESG”).
The Complaint alleges that throughout the Class Period, Defendants and certain of KLX current and former executive officers and directors have materially misrepresented the value of the Company's identifiable intangible assets and goodwill associated with KLX's Energy Services Group ("ESG"), as well as its policies and methodology related to the calculation of risk, goodwill, and asset impairment.
On November 12, 2015, before the stock market opened, KLX announced preliminary financial results for the quarter ended November 30, 2015. In the press release, the Company disclosed that “[d]uring the third quarter of 2015, the Company performed an interim asset impairment test.” Based on that asset impairment test, KLX stated, “the company expects to recognize a non-cash, after-tax asset impairment charge of approximately $435 million related to its Energy Services Group.”
As a result of the news, the trading price of KLX’s common stock plunged from a closing price of $39.00 on November 11, 2015 to close at $32.11 on November 12, 2015, a single-day loss of approximately 16%.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Britain Courts Anthropic Amid US Defense Department Dispute
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 



